PSMA+ mCRPC

PSMA+ mCRPC

PARP Inhibitor Benefit in Patients With Metastatic Castration-Resistant Prostate Cancer

clinical topic updates
By Neeraj Agarwal, MD, FASCO

PSMA+ mCRPC

The Evolving Role of Prostate-Specific Membrane Antigen Positron Emission Tomography Across the Prostate Cancer Disease Continuum

patient care perspectives
By Neeraj Agarwal, MD, FASCO

PSMA+ mCRPC

Second Taxane for Progression After Triplet Therapy: Treatment Considerations

clinical topic updates
By William K. Oh, MD

PSMA+ mCRPC

On-Treatment Biomarkers During Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

clinical topic updates
By William K. Oh, MD

PSMA+ mCRPC

Optimizing Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer

patient care perspectives
By William K. Oh, MD